e10vqza
 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q/A

     
x
  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
    For the Quarterly Period Ended September 30, 2004
 
    or
 
o
   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
    For the transition period from           to

Commission File No. 000-29089

Antigenics Inc.

(Exact name of Registrant as Specified in its Charter)
     
Delaware   06-1562417
(State of Incorporation)   (I.R.S. Employer Identification Number)

630 Fifth Avenue, Suite 2100, New York, New York, 10111

(Address of Principal Executive Offices)

(212) 994-8200

(Registrant’s Telephone Number, including Area Code)

     Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes þ          No o

      Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).     Yes þ          No o

      Number of shares outstanding of the registrant’s Common Stock as of October 29, 2004: 45,522,179 shares

 

EXPLANATORY NOTE

      We are filing this amendment to our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2004, originally filed with the Securities and Exchange Commission on November 9, 2004, solely for the purpose of including the signatures of our chief executive officer and chief financial officer and the exhibit index. These signatures and the index were omitted from the original filing of our Form 10-Q for the period ended September 30, 2004 due to a technical error by our EDGAR filing agent.

      This amendment does not amend any information previously filed in our Form 10-Q for the quarterly period ended September 30, 2004.

2

 

ANTIGENICS INC.

SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  ANTIGENICS INC.

  By:  /s/ GARO H. ARMEN
 
  Garo H. Armen Ph.D.
  Chairman and Chief Executive Officer

  By:  /s/ PETER THORNTON
 
  Peter Thornton
  Chief Financial Officer

Date: November 9, 2004

3

 

EXHIBIT INDEX

         
Exhibit No. Description
  Exhibit  31.1     Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  Exhibit  31.2     Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  Exhibit  32.1     Certification pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

4

 

ANTIGENICS INC.

SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 10-Q/ A to be signed on its behalf by the undersigned thereunto duly authorized.

  ANTIGENICS INC.

  By:  /s/ GARO H. ARMEN
 
  Garo H. Armen Ph.D.
  Chairman and Chief Executive Officer

  By:  /s/ PETER THORNTON
 
  Peter Thornton
  Chief Financial Officer

Date: November 10, 2004

5

 

EXHIBIT INDEX

         
Exhibit No. Description
  Exhibit  31.1     Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  Exhibit  31.2     Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  Exhibit  32.1     Certification pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

6